Fosamax and Osteonecrosis of the Jaw: Understanding Causation and Pathophysiology

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Surveillance to Targeted Drug Safety Monitoring

Historically, public access to structured health data has centered on general quality metrics and practitioner oversight. Resources such as the National Practitioner Data Bank, state medical board records, and Hospital Compare from the U.S. Department of Health and Human Services have provided a foundation for evaluating broad patterns in medical care and patient safety. These datasets, often used for educational or research purposes, reflect a legacy focus on systemic performance and regulatory compliance. As the informational landscape evolves, a more targeted concern emerges: the need to trace specific pharmaceutical exposures and their documented adverse outcomes. In particular, the transition from general health surveillance to occupational and patient-level risk assessment becomes critical when examining drugs with known serious side effects. One such area involves bisphosphonate therapy, where long-term use has been associated with rare but severe bone complications. This shift in focus requires moving from aggregate hospital data and practitioner discipline records toward granular, exposure-specific reporting systems. Databases like the FDA’s Manufacturer and User Facility Device Experience (MAUDE) and adverse event repositories now serve as primary sources for linking drug exposure to patient harm. The pivot from general health information to occupational exposure concern is thus marked by a change in data granularity: from population-level oversight to individual case-level scrutiny, particularly for therapies where the risk-benefit profile demands close monitoring.

Bridging to Fosamax: Mechanism of Action and Adverse Effects

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which increases bone mass and reduces fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Pathophysiology: How Fosamax Triggers Osteonecrosis of the Jaw

The pathophysiology linking Fosamax to ONJ involves the drug's potent inhibition of osteoclast-mediated bone remodeling. Bisphosphonates like alendronate accumulate in bone, particularly at sites of high turnover such as the jaw, and suppress osteoclast activity. This suppression reduces the normal process of bone resorption and renewal, leading to compromised bone quality and impaired healing capacity. Multiscale characterization of jawbone in animal models treated with bisphosphonates has provided information that helps understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). These studies examine properties such as tissue mineral density distribution and mechanical stability of teeth in the alveolar socket, which are altered by bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077/). The clinical presentation of ONJ typically involves exposed bone in the mandible or maxilla that persists for more than eight weeks. Diagnosis is based on clinical examination and imaging, with a history of bisphosphonate use being a key factor.

Risk Factors and Causation Evidence

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding causation, the time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, and a subset of patients have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship between bisphosphonate exposure and ONJ. In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event that may not be captured in typical trial populations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Warnings and Clinical Management

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, describing its association with bisphosphonates, known risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use should be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation-related considerations include the timeline between exposure and documented harm. The onset of ONJ can occur within days to months after starting Fosamax, and the condition is often triggered by dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The recurrence of symptoms upon rechallenge further supports a causal link. Patients with known risk factors, such as cancer, corticosteroid use, or poor oral hygiene, may be at higher risk. The duration of bisphosphonate therapy is also a factor, as longer exposure increases the likelihood of ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In summary, Fosamax can trigger osteonecrosis of the jaw through its suppression of bone remodeling, leading to compromised healing in the jawbone. The condition is rare but serious, with known risk factors and a variable onset timeline. Warnings in the prescribing information address these risks, and discontinuation of therapy may reduce the risk for patients undergoing invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, leading to accumulation in high-turnover sites like the jaw. This suppression of bone remodeling compromises bone quality and healing capacity, which can trigger osteonecrosis of the jaw (ONJ). Studies have shown altered tissue mineral density and mechanical stability in jawbone after bisphosphonate treatment (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the known risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid conditions like periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Longer duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How long after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months. Most patients experience relief after discontinuing the drug, and recurrence upon rechallenge supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.